Pharvaris has completed patient enrollment for its proof-of-concept CHAPTER-1 clinical trial that will evaluate the safety and effectiveness of deucrictibant as a prophylactic, or preventive, treatment for adults with hereditary angioedema (HAE). While the global Phase 2 CHAPTER-1 study (NCT05047185) is still on hold in the U.S.,…
Enrollment for the Phase 2 portion of a clinical trial testing NTLA-2002, Intellia Therapeutics’ experimental gene-editing therapy for hereditary angioedema (HAE), is expected to be completed this year. This is the result of “substantial interest from physicians and patients to participate in the NTLA-2002 clinical program,” the company…
Treatment with tranexamic acid may ease symptoms and prevent intubation in people who develop angioedema after receiving certain high blood pressure medications called angiotensin-converting enzyme (ACE) inhibitors, a review of published studies shows. The findings also suggest tranexamic acid may be more advantageous than other therapies currently used to…
A 26-year-old woman developed a rare case of non-episodic angioedema associated with eosinophilia (NEAE) following her second dose of the Pfizer-BioNTech COVID-19 vaccine, according to a study from Japan. Eosinophilia refers to higher-than-normal levels of a type of immune cells called eosinophils. Her NEAE symptoms were resolved completely two months…
The use of Dupixent (dupilumab), an approved treatment for skin and respiratory conditions linked to a specific type of inflammation, led to the development of angioedema in a woman in her 40s, as described in a new case report from U.S. researchers. The woman, who had a type…
People with hereditary angioedema (HAE) are able to recognize early signs of swelling attacks and the need to get prompt on-demand treatment to manage them, new research highlights. Findings were presented by KalVista Pharmaceuticals in a series of posters at the recent U.S. Hereditary Angioedema Association (HAEA)…
The U.S. Food and Drug Administration (FDA) has given STAR-0215 fast track status to help speed up its development and make it available to patients sooner. An experimental medication to prevent swelling attacks in hereditary angioedema (HAE), with dosing once every three or six months, STAR-0215 is in…
BioCryst Pharmaceuticals is teaming up with Er-Kim Pharmaceuticals to commercialize Orladeyo (berotralstat) in Turkey. Orladeyo is an oral therapy, taken once a day, to prevent swelling attacks with hereditary angioedema (HAE). Er-Kim, based in Istanbul, partners with pharma companies to bring new therapies to markets around…
Pediatricians in Brazil show, in general, a low level of knowledge of hereditary angioedema (HAE), according to a recent study. Even though those who were board-certified specialists in allergy and immunology were more knowledgeable than those who weren’t, their level of knowledge was still considered unsatisfactory. “Based on the…
Healthcare costs continuously dropped for people with hereditary angioedema (HAE) who were on long-term preventive treatment with Takhzyro (lanadelumab), according to a retrospective analysis of healthcare insurance claims from a U.S. database. Findings were reported in a study, “Real-world changes in costs over time among…
Get regular updates to your inbox.